Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Swiss Group for Clinical Cancer Research)"
Count: 135
Selected: 0
NCT02467582Adjuvant Aspirin Treatment for Colon Cancer Patients
NCT03937843Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
NCT00030732Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer
NCT02451111Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
NCT03905343Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
NCT06452394NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
NCT06401980Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06358573Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
NCT06114108Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients
NCT06090162LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma
NCT04630730Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
NCT04629781Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC
NCT04604067Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
NCT04480372SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
NCT04472949Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
NCT04245514Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
NCT04024475Prostate Cancer Biobank
NCT03993678Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
NCT03921996Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer
NCT03886649Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
NCT03786198Activity Program During Aromatase Inhibitor Therapy
NCT03762122Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)
NCT03708003Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
NCT036206691st Line Durvalumab in PS 2 NSCLC Patients
NCT03524898NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma
NCT03520985Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma
NCT03406650Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.
NCT03387917TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
NCT03297593Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
NCT03213301Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
NCT02964689Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
NCT02945813SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
NCT02933801ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.
NCT02910843Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer
NCT02877550Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
NCT02833766Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
NCT02640534Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone
NCT02597075Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy
NCT02572843Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
NCT02404506Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer
NCT02371447VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
NCT02356458Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
NCT02311569Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation
NCT02311543Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer
NCT02188537Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
NCT02067741CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer
NCT02058056Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLC
NCT02053311Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
NCT02051218Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
NCT01954355LDE225 and Paclitaxel in Solid Tumors